Founded with the mission to discover and develop unique antibody drugs for major untreated diseases, Abalone Bio focuses on creating therapies that target G-protein coupled receptors (GPCRs). These receptors are crucial for cellular responses to chemical signals and are implicated in numerous biological processes. Abalone Bio's innovative technology aims to modulate these receptors, offering potential treatments for diseases that current drugs cannot effectively address. Their market focus includes developing safer and more effective antibody drugs compared to traditional small molecules.

Abalone Bio has attracted notable attention from key figures in the biotechnology sector and secured investments from prominent venture capital firms. Their pioneering work in antibody drug discovery has led to significant advancements in targeting GPCRs, a class of receptors that remains largely unexplored despite its therapeutic potential. The company's impact is underscored by its commitment to addressing unmet medical needs, positioning itself as a leader in the next generation of antibody therapeutics.